FY2024 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Zacks Research reduced their FY2024 earnings estimates for Bruker in a note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.40 per share for the year, down from their prior forecast of $2.60. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.75 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.59 EPS, FY2025 earnings at $2.78 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $0.84 EPS, Q3 2026 earnings at $0.82 EPS and FY2026 earnings at $3.42 EPS.

Other equities analysts have also issued reports about the stock. Citigroup reduced their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Barclays reduced their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. TD Cowen reduced their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company reduced their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

NASDAQ BRKR opened at $58.38 on Wednesday. The stock has a market cap of $8.85 billion, a P/E ratio of 28.07, a PEG ratio of 3.95 and a beta of 1.20. The company’s 50-day simple moving average is $61.18 and its 200 day simple moving average is $64.29. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The business had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s revenue was up 16.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.74 EPS.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date is Monday, December 2nd. Bruker’s dividend payout ratio is currently 9.62%.

Insider Activity

In related news, CEO Frank H. Laukien acquired 100,000 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Several large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. boosted its holdings in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. True Wealth Design LLC raised its position in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker during the second quarter worth approximately $52,000. Finally, GAMMA Investing LLC increased its stake in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after acquiring an additional 388 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.